Taiwan Advance Bio-Pharmaceutical, Inc.(TW:4186)
NT$6.95+0.05 (+3.42%)
TW:4186
Taiwan Advance Bio-Pharmaceutical, Inc. financials statements
NT$6.95
At close:+0.05 (+3.42%)
Taiwan Advance Bio-Pharmaceutical, Inc. (4186) Ratios
Taiwan Advance Bio-Pharmaceutical, Inc. Ratios
TW:4186's free cash flow for Q2 2026 was NT$-595.00K. For the 2026 fiscal year, TW:4186's free cash flow was decreased by NT$-5.78M and operating cash flow was NT$5.19M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.98 | 0.96 | 0.82 | 1.07 | 1.09 |
| Quick Ratio | 0.90 | 0.88 | 0.75 | 0.97 | 0.99 |
| Cash Ratio | 0.52 | 0.45 | 0.57 | 0.65 | 0.65 |
| Solvency Ratio | 0.10 | 0.10 | 0.03 | 0.07 | -0.19 |
| Operating Cash Flow Ratio | 0.19 | 0.03 | 0.04 | -0.08 | -0.20 |
| Short-Term Operating Cash Flow Coverage | 0.24 | 0.05 | 0.05 | -0.12 | -0.35 |
| Net Current Asset Value | NT$ -194.88M | NT$ -191.54M | NT$ -255.35M | NT$ -202.00M | NT$ -204.63M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.37 | 0.35 | 0.43 | 0.41 | 0.36 |
| Debt-to-Equity Ratio | 0.96 | 0.92 | 1.37 | 1.19 | 1.06 |
| Debt-to-Capital Ratio | 0.49 | 0.48 | 0.58 | 0.54 | 0.51 |
| Long-Term Debt-to-Capital Ratio | 0.18 | 0.19 | 0.26 | 0.30 | 0.31 |
| Financial Leverage Ratio | 2.62 | 2.64 | 3.20 | 2.89 | 2.96 |
| Debt Service Coverage Ratio | 0.23 | 0.29 | 0.10 | 0.20 | -0.56 |
| Interest Coverage Ratio | 4.45 | 6.04 | 0.58 | 1.24 | -13.83 |
| Debt to Market Cap | 0.27 | 0.16 | 0.22 | 0.18 | 0.15 |
| Interest Debt Per Share | 3.10 | 2.70 | 3.68 | 3.30 | 2.93 |
| Net Debt to EBITDA | 2.71 | 2.55 | 6.33 | 3.48 | -1.26 |
| Profitability Margins | |||||
| Gross Profit Margin | 62.31% | 68.88% | 62.81% | 60.51% | 51.28% |
| EBIT Margin | 7.95% | 8.48% | -1.29% | 3.09% | -43.97% |
| EBITDA Margin | 13.34% | 14.30% | 6.90% | 11.94% | -31.51% |
| Operating Profit Margin | 7.95% | 12.66% | 1.35% | 2.39% | -42.25% |
| Pretax Profit Margin | 7.44% | 6.38% | -3.60% | 1.16% | -47.03% |
| Net Profit Margin | 7.69% | 6.46% | -3.38% | 1.00% | -48.70% |
| Continuous Operations Profit Margin | 7.69% | 6.46% | -3.38% | 1.00% | -48.70% |
| Net Income Per EBT | 103.28% | 101.21% | 93.81% | 86.02% | 103.57% |
| EBT Per EBIT | 93.63% | 50.41% | -266.74% | 48.41% | 111.31% |
| Return on Assets (ROA) | 3.76% | 3.38% | -1.43% | 0.45% | -16.61% |
| Return on Equity (ROE) | 9.84% | 8.92% | -4.57% | 1.30% | -49.09% |
| Return on Capital Employed (ROCE) | 6.11% | 10.25% | 0.99% | 1.64% | -21.94% |
| Return on Invested Capital (ROIC) | 4.26% | 7.32% | 0.60% | 1.01% | -16.88% |
| Return on Tangible Assets | 3.76% | 3.38% | -1.43% | 0.45% | -16.85% |
| Earnings Yield | 2.79% | 1.61% | -0.75% | 0.20% | -7.14% |
| Efficiency Ratios | |||||
| Receivables Turnover | 3.71 | 3.63 | 6.10 | 5.08 | 3.61 |
| Payables Turnover | 27.78 | 44.17 | 31.27 | 36.34 | 27.80 |
| Inventory Turnover | 6.46 | 5.89 | 5.55 | 5.36 | 4.92 |
| Fixed Asset Turnover | 1.44 | 1.51 | 1.28 | 1.24 | 0.94 |
| Asset Turnover | 0.49 | 0.52 | 0.42 | 0.45 | 0.34 |
| Working Capital Turnover Ratio | -45.88 | -10.42 | -15.62 | 16.05 | 3.16 |
| Cash Conversion Cycle | 141.67 | 154.20 | 113.95 | 129.88 | 162.23 |
| Days of Sales Outstanding | 98.31 | 100.54 | 59.88 | 71.89 | 101.13 |
| Days of Inventory Outstanding | 56.50 | 61.92 | 65.75 | 68.03 | 74.23 |
| Days of Payables Outstanding | 13.14 | 8.26 | 11.67 | 10.04 | 13.13 |
| Operating Cycle | 154.81 | 162.47 | 125.63 | 139.92 | 175.36 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 0.56 | 0.09 | 0.14 | -0.23 | -0.53 |
| Free Cash Flow Per Share | 0.19 | 0.05 | 0.01 | -0.31 | -0.69 |
| Dividend Paid and CapEx Coverage Ratio | 1.52 | 2.10 | 1.06 | -2.83 | -3.39 |
| Capital Expenditure Coverage Ratio | 1.52 | 2.10 | 1.06 | -2.83 | -3.39 |
| Operating Cash Flow Coverage Ratio | 0.19 | 0.04 | 0.04 | -0.07 | -0.19 |
| Operating Cash Flow to Sales Ratio | 0.14 | 0.02 | 0.04 | -0.06 | -0.20 |
| Free Cash Flow Yield | 1.71% | 0.31% | 0.05% | -1.80% | -3.75% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 35.97 | 63.00 | -132.50 | 488.64 | -13.98 |
| Price-to-Sales (P/S) Ratio | 2.75 | 4.00 | 4.48 | 4.86 | 6.82 |
| Price-to-Book (P/B) Ratio | 3.52 | 5.53 | 6.05 | 6.33 | 6.88 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 58.41 | 324.59 | 2121.99 | -55.54 | -26.66 |
| Price-to-Operating Cash Flow Ratio | 19.86 | 170.23 | 112.26 | -75.17 | -34.53 |
| Price-to-Earnings Growth (PEG) Ratio | 1.50 | -0.20 | 0.30 | -4.76 | -0.60 |
| Enterprise Value Multiple | 23.33 | 30.54 | 71.22 | 44.22 | -22.91 |
| Enterprise Value | 1.14B | 1.55B | 1.55B | 1.68B | 1.76B |
| EV to EBITDA | 23.33 | 30.54 | 71.22 | 44.22 | -22.91 |
| EV to Sales | 3.11 | 4.37 | 4.92 | 5.28 | 7.22 |
| EV to Free Cash Flow | 66.09 | 354.20 | 2328.88 | -60.28 | -28.21 |
| EV to Operating Cash Flow | 22.47 | 185.76 | 123.20 | -81.59 | -36.54 |
| Tangible Book Value Per Share | 3.17 | 2.85 | 2.63 | 2.68 | 2.57 |
| Shareholders’ Equity Per Share | 3.17 | 2.85 | 2.63 | 2.72 | 2.68 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.03 | -0.01 | 0.06 | 0.14 | -0.04 |
| Revenue Per Share | 4.05 | 3.94 | 3.55 | 3.54 | 2.70 |
| Net Income Per Share | 0.31 | 0.25 | -0.12 | 0.04 | -1.32 |
| Tax Burden | 1.03 | 1.01 | 0.94 | 0.86 | 1.04 |
| Interest Burden | 0.94 | 0.75 | 2.78 | 0.38 | 1.07 |
| Research & Development to Revenue | 0.03 | 0.05 | 0.05 | 0.05 | 0.19 |
| SG&A to Revenue | 0.51 | 0.51 | 0.56 | 0.53 | 0.75 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 1.80 | 0.37 | -1.11 | -6.50 | 0.42 |
Currency in TWD
